Mirati Therapeutics Inc
NASDAQ:MRTX
Mirati Therapeutics Inc
Total Receivables
Mirati Therapeutics Inc
Total Receivables Peer Comparison
Competitive Total Receivables Analysis
Latest Figures & CAGR of Competitors
Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Mirati Therapeutics Inc
NASDAQ:MRTX
|
Total Receivables
$18m
|
CAGR 3-Years
129%
|
CAGR 5-Years
105%
|
CAGR 10-Years
57%
|
|
Abbvie Inc
NYSE:ABBV
|
Total Receivables
$11.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
16%
|
CAGR 10-Years
10%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Receivables
$4.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Receivables
$6.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
10%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Receivables
$1.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
33%
|
CAGR 10-Years
40%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Receivables
$5.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
18%
|
CAGR 10-Years
17%
|
See Also
What is Mirati Therapeutics Inc's Total Receivables?
Total Receivables
18m
USD
Based on the financial report for Sep 30, 2023, Mirati Therapeutics Inc's Total Receivables amounts to 18m USD.
What is Mirati Therapeutics Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
57%
Over the last year, the Total Receivables growth was 959%. The average annual Total Receivables growth rates for Mirati Therapeutics Inc have been 129% over the past three years , 105% over the past five years , and 57% over the past ten years .